1. Home
  2. ETON vs AUTL Comparison

ETON vs AUTL Comparison

Compare ETON & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$18.93

Market Cap

411.9M

Sector

Health Care

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.44

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
AUTL
Founded
2017
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
411.9M
431.2M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
ETON
AUTL
Price
$18.93
$1.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$31.00
$8.50
AVG Volume (30 Days)
291.1K
1.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.33
EPS
N/A
N/A
Revenue
$39,011,000.00
$10,120,000.00
Revenue This Year
$107.23
$669.62
Revenue Next Year
$29.72
$79.78
P/E Ratio
N/A
N/A
Revenue Growth
23.29
496.00
52 Week Low
$11.09
$1.11
52 Week High
$23.00
$2.70

Technical Indicators

Market Signals
Indicator
ETON
AUTL
Relative Strength Index (RSI) 64.96 40.70
Support Level $16.04 $1.27
Resistance Level $20.01 $1.52
Average True Range (ATR) 1.08 0.11
MACD 0.10 -0.03
Stochastic Oscillator 70.56 0.96

Price Performance

Historical Comparison
ETON
AUTL

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Share on Social Networks: